Skip to main content


  • Clinical trial follows encouraging results from five patients with confirmed COVID-19 infections administered RUCONEST® to treat the related severe pneumonia
  • First patient at the University Hospital Basel, Basel, Switzerland, with confirmed COVID-19 infection has been enrolled in a clinical trial to investigate the use of RUCONEST® to prevent severe SARS-CoV-2 infection in hospitalised patients with COVID-19
  • Study to be extended to additional clinical centres in Switzerland, Mexico and Brazil
  • Additional study in multiple centres in the US in final stages of preparation

RUCONEST®’s multiple interactions with key inflammation pathways therefore make it a promising candidate to prevent the severe complications observed in COVID-19 patients.

- Bruno Giannetti - CMO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline